Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Status:
Terminated
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost
impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current
treatment. These patients have few options to treat their lung infection. Nitric oxide has
broad bactericidal and virucidal properties. It has been shown that nitric oxide was safe to
be inhaled for similar cystic fibrosis patients and reduced drug resistant bacteria in the
lungs. Further, research indicates that clinical isolates of NTM, Burkholderia spp,
Aspergillus spp and Corona-like viruses can be eradicated by 160ppm NO exposure in the
laboratory petri dish. This is not the first time inhaled NO treatment has been used in
patients with difficult lung infections. This study will provide more data to see if NO
therapy can reduce the bacterial load in the lungs, help the patients breath better; and in
the case of COVID-19 act as a anti-viral agent resulting in the reduction of incidence of
oxygen therapy, mechanical assistance of BIPAP, CPAP, intubation and mechanical ventilation
during the study period.